A main neurogenic niche in the adult human brain is the subventricular zone (SVZ). Recent data suggest that the progenitors that are born in the human SVZ migrate via the rostral migratory stream (RMS) towards the olfactory bulb (OB), similar to what has been observed in other mammals. A subpopulation of astrocytes in the SVZ specifically expresses an assembly-compromised isoform of the intermediate filament protein glial fibrillary acidic protein (GFAP-d). To further define the phenotype of these GFAP-d expressing cells and to determine whether these cells are present throughout the human subventricular neurogenic system, we analysed SVZ, RMS and OB sections of 14 aged brain donors (ages 74-93). GFAP-d was expressed in the SVZ along the ventricle, in the RMS and in the OB. The GFAP-d cells in the SVZ co-expressed the neural stem cell (NSC) marker nestin and the cell proliferation markers proliferating cell nuclear antigen (PCNA) and
Introduction
The adult human brain contains two regions where continuous neurogenesis takes place, i.e. the subventricular zone (SVZ) (Sanai et al., 2004; Quinones-Hinojosa et al., 2006) and the subgranular zone in the hippocampal dentate gyrus (Eriksson et al., 1998; Roy et al., 2000) . In particular, the SVZ maintains a level of plasticity into adulthood and can respond to certain neurological conditions, such as stroke and Huntington's disease, by increasing the number of neuron forming precursor cells that can potentially replace damaged neurons. In animal models of brain trauma, disease and stroke, the SVZ responds by producing new precursor cells, which migrate to the damaged areas and form new regionally specific neurons (Parent et al., 2002; Cooper & Isacson, 2004) . In the human brain, a similar response seems to occur after ischaemia (Macas et al., 2006) . The SVZ can react in this way because it is situated close to the striatum, which is affected in Parkinson's disease and Huntington's disease and it receives nutrients from the cerebrospinal fluid in the lateral ventricle (for review, see (Curtis et al., 2007a) ). One of the key questions that remain to be answered is which cells in the SVZ are responsible for ultimately producing the new cells in the human SVZ.
The composition of the human SVZ is different from that of the more studied rodent species because of the presence of a hypocellular gap between the ependymal layer and the dense astrocytic ribbon, the latter of which contains the neural precursors (Quinones-Hinojosa et al., 2006) . There are indications that a subpopulation of astrocytes in this ribbon, the neurogenic astrocytes, proliferate in vivo and behave as multipotent precursor cells in vitro (Sanai et al., 2004) , implying that SVZ astrocytes of the adult human brain indeed are neural stem cells (NSCs). Within the SVZ, three major cell types exist, one of which is the neurogenic astrocyte known as B-cell (Doetsch et al., 1997) , which is a slowly proliferating cell that asymmetrically divides to form a pool of fast-dividing neural progenitor cells, the C-cells. Type C-cells in turn differentiate into type A-cells, called neuroblasts, which migrate through the rostral migratory stream (RMS) into the olfactory bulb (OB), where they differentiate into new interneurons (Curtis et al., 2007b) . The existence of an RMS in the human brain, long thought absent, was recently described by Curtis et al., (2007b) . Recently, we have shown that NSCs are still present in the SVZ of elderly subjects, including cases with neurodegenerative diseases, such as Alzheimer's disease (Leonard et al., 2009) .
NSCs express certain intermediate filament (IF) proteins, and some reports claim the specificity of these for labelling NSCs. IFs are highly versatile cytoskeletal structures that have a major function in cell signalling and migration (Lepekhin et al., 2001; Pallari & Eriksson, 2006; Herrmann et al., 2007) . One IF expressed in NSCs is nestin, widely regarded as specific for NSCs (for review, see (Gilyarov, 2008) ), but conflicting reports reveal nestin expression in both reactive and mature astrocytes (Lin et al., 1995; Gu et al., 2002) . Our laboratory has been interested in specific IF expression as they relate to NSCs. To this end, our previous work has revealed that SVZ astrocytes in the human brain express the IF protein glial fibrillary acidic protein d (GFAP-d) (Roelofs et al., 2005) , one of the seven splice variants of GFAP (Hol et al., 2003; Quinlan et al., 2007) , the main IF protein in astrocytes (Eng et al., 2000) ). Moreover, we recently have described that GFAP-d is expressed in radial glia and SVZ progenitors of the human foetal brain (Middeldorp et al., 2010) , substantiating our earlier findings that this specific GFAP isoform is a marker for NSC. GFAP-d (also named GFAP-e (Nielsen et al., 2002) ) has a unique 41 amino acid carboxy-terminus. This unique tail domain endows the protein with several properties distinct from GFAP-a, which are likely to have important functional consequences for the IF network formed in the SVZ astrocytes. Firstly, GFAP-d is an assembly-compromised form of GFAP (Nielsen et al., 2002; Roelofs et al., 2005; Perng et al., 2008) and its presence in the IF network changes the composition of the IF network and its associated proteins, such as aB-crystallin (Perng et al., 2008) . The network can tolerate up to 10% of the GFAP-d isoform, which is approximately the amount found in the central nervous system (Perng et al., 2008) . A second property of GFAP-d is its ability to interact with presenilins (Nielsen et al., 2002) , which are essential partners in the gamma-secretase complex. This complex cleaves the transmembrane proteins Notch and amyloid precursor protein (APP) inside the membrane region and therefore is critical for Notch and APP signalling (Selkoe & Kopan, 2003) . Notch signalling is required for maintenance of NSC populations in both the developing and adult brain (Alexson et al., 2006) , and Notch1 expression can be found in SVZ astrocytes and neuroblasts in the adult rodent brain (Givogri et al., 2006) . Thirdly and finally, the induced expression of GFAP-d in vitro results in an increased phosphorylation of Jnk (Perng et al., 2008) . In the developing brain, Jnk is involved in NSC proliferation (Wang et al., 2007) , migration (Mizuno et al., 2005) , and differentiation (Kim et al., 2007) .
Localization of GFAP-d and its ability to modulate signalling pathways important for NSCs suggest that GFAP-d is expressed by NSCs in the adult SVZ. Here, we have studied the expression of GFAP-d in the SVZ, RMS and OB in the adult human brain. We provide evidence that the GFAP-d expressing cells may indeed be quiescent adult NSCs, as they are present throughout the human adult neurogenic system, in a subpopulation of proliferating astrocytes in the SVZ, and in neurosphere cultures isolated from postmortem adult human SVZ material.
Results
GFAP-d is robustly expressed in an astrocytic ribbon of variable width along the full length of the SVZ
We have previously described that GFAP-d is expressed in the SVZ along several brain structures and subpial layers of the adult human brain (Roelofs et al., 2005) . In the current study, we have systematically studied its expression pattern throughout the SVZ of five aged control brains at three standardized locations (see Fig. 1A , and Experimental procedures). When staining these three areas for GFAP-d, we observed a band of immunostaining in the SVZ throughout the three sampled locations. The cells in this band often had an elongated morphology, parallel to the ependymal lining of the SVZ. The width of the immunoreactive band, which ranged from 20 to 200 lm ( Fig. 1B) , was not constant within the three SVZ areas of one donor and showed also large variability among donors. We have performed a correlation analysis between the variability and several characteristics of the donors, such as age, sex, postmortem delay and medication used, and found no significant correlations. Figure 1C -E shows a typical example of the strong variability of the thickness of the band of GFAP-d expressing astrocytes throughout the SVZ of one donor. The SVZ regions of the same donor stained for all GFAP isoforms revealed many more GFAP positive cells and encompassed labelling in the caudate nucleus, SVZ and in the hypocellular gap ( Fig. 1F-H) . These data substantiate our earlier findings that GFAP-d is expressed in a subset of astrocytes in the SVZ, forming a ribbon. In addition, we provide a first report on the large variation in the width of the astrocytic ribbon within and between donors, and in the quantity of GFAP-d positive cells in the SVZ.
GFAP-d is expressed in immature, proliferative SVZ astrocytes with stem cell characteristics
To establish the specific phenotype of the cells in the astrocytic ribbon that express GFAP-d, we applied a double-immunolabelling technique using various astrocyte-specific markers in the three SVZ areas. Results of confocal analysis are shown in Fig. 2 ; images showing anatomical localization are shown in supplemental Fig. S1 . GFAP-d was expressed in a subpopulation of astrocytes that also expressed the astrocyte marker GFAP-a ( Fig. 2A) , as shown by clear co-localization with an antibody specific for the C-terminus of GFAP. The immature astrocyte GFAP-d marker vimentin, an IF protein, also co-localized with GFAP-d ( Fig. 2B ). To the contrary, the calcium binding protein S100B, and the enzyme glutamine synthetase (GS), a marker of fully differentiated astrocytes, were not expressed in GFAP-d cells. S100B was expressed in a distinct cell population in the SVZ (Fig. 2C ), most likely representing more mature niche astrocytes; expression of GS was only found in cells of the parenchyma and not in the SVZ (Fig. 2D ). GFAP-d was not expressed by postmitotic neurons, as was shown by the absence of co-localization with NeuN (data not shown).
To investigate whether GFAP-d cells in the aged SVZ are NSCs, we studied the co-expression of GFAP-d with proliferation markers and markers for NSCs. Results of confocal analysis are shown in Fig. 3 ; images showing anatomical localization are shown in supplemental Fig. S2 . We found that all GFAP-d positive cells also express the proliferation marker proliferating cell nuclear antigen (PCNA; Fig. 3A ), the mitosis marker minichromosome maintenance complex component 2 (Mcm2; Fig. 3B ) and the transcription factor Sox2 (Fig. 3C ). The latter marker showed staining in both cell nuclei and in cytoplasm, which has been described before for the human brain (Baer et al., 2007) . The phosphorylated form of the histone H3 protein (pHH3) was not expressed in GFAP-d positive cells (Fig. 3D ), and also no doublelabelling with Ki-67, another proliferation marker, was seen ( Fig. 3E ); in fact very few pHH3 and Ki-67 positive cells were present in the SVZ, which is in agreement with earlier reports (Kukekov et al., 1999) . Attempts to co-localize GFAP-d with CD133 were unsuccessful in this paraffin-embedded material.
We also studied co-localization with the thymidine analogue BrdU, which labels dividing cells in the S-phase. In one of the brains treated with BrdU, many BrdU-positive nuclei were found in the SVZ near the caudate nucleus, many of which were GFAP-d-positive ( Fig. 3F ). Besides the SVZ astrocytes, many fibres around BrdU positive ependymal cells were GFAP-d positive. Deeper into the brain parenchyma, BrdU positive nuclei were scarce. In the second human BrdU case, much less BrdU labelling was found, and there was a corresponding reduction in the number of double-positive cells. In the second BrdU case, the time from BrdU injection to postmortem examination was protracted compared to the first case. Our data so far demonstrate that GFAP-d positive cells are proliferative, which is one indication that these cells are indeed NSCs. Subsequently, we studied whether the cells co-express markers for different stages of stem cell differentiation. We observed considerable co-expression between GFAP-d and nestin (B-cells; Fig. 3G ). However, this pattern was variable throughout the SVZ; we observed regions with almost complete overlap between the stainings, as well as locations with minimal overlap. We also observed that GFAP-d positive cells only rarely expressed the C-cell marker EGF-R ( Fig. 3H) or the A-cell marker b-III-tubulin ( Fig. 3I ). Attempts to co-localize GFAP-d with PSA-NCAM or DCX, using different antibodies (as mentioned in supplementary Table S1), were unsuccessful.
GFAP-d is expressed in the glial net surrounding the RMS
In 2007, the first details emerged about the existence of the RMS in the human brain, although organized differently than in mice (Curtis et al., 2007b) . Furthermore, Alonso et al. showed
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07-046 SVZ3 07-014 SVZ1 that astrocytes in the rodent RMS are neurogenic (Alonso et al., 2008) . Therefore, we examined the aged human RMS for the presence of GFAP-d. Indeed, we found GFAP-d to be highly expressed throughout the RMS (Fig. 4) . In fact, GFAP-d is a very reliable and robust marker of the RMS in the human brain. In sagittal sections taken from the RMS, the dorsal and rostral limbs of the RMS were visible in a number of sections ( Fig. 4A -C). The dorsal limb of the RMS contained a broad band of GFAPd immunoreactive stellate-shaped cells with cell bodies that were about 8-10 lm in diameter and had many long processes. Fewer GFAP-d immunoreactive cells were found in the rostral limb of the RMS. There was large variation in the number of GFAP-d immunoreactive cells in the RMS within and between donors.
In frontal sections from the striatum, which we studied for different purposes, the dorsal limb of the RMS was visible. In these sections, we observed that in double immunostaining of GFAP-d with PCNA, PCNA was highly expressed in the centre of the stream of the RMS, whereas GFAP-d positive astrocytes were predominantly found at the border of this stream (Fig. 4D) . No co-localization was found between GFAP-d and PCNA in the dorsal limb of the RMS (Fig. 4D ).
GFAP-d is expressed in proliferative cells in the olfactory bulb
The OB and olfactory tract (OT) were also highly enriched in GFAP-d positive cells (Fig. 5 ). In the centre of the OT, the GFAP-d positive cells seemed to be organized in streams. Most GFAP-d positive cells were however located in the outer layers of the OT (Fig. 5B ). In the OB, GFAP-d positive cells were primarily found in the olfactory nerve layer and glomerular layer ( Fig. 5C and D) . Few cells were also localized within the external plexiform layer and granule cell layer. Double-labelling of GFAP-d with PCNA in the OB ( Fig. 5E and supplemental Fig. S3E ) showed that the GFAP-d cells were proliferative. As the cells were negative for b-III-tubulin ( Fig. 5F and supplemental Fig. S3F ), we conclude that the GFAP-d positive cells were not neuroblasts. In contrast to the SVZ, we very rarely observed co-expression of vimentin and GFAP-d ( Fig. 5G and supplemental Fig. S3G ).
GFAP-d is expressed in postmortem human adult neurospheres
To obtain further evidence that GFAP-d is expressed in adult NSCs, we aimed at determining whether GFAP-d is expressed in neurospheres derived from the SVZ of human adult brain. Although the neurosphere assay has some limitations (Reynolds & Rietze, 2005) , it has long been used to assess whether a particular area of the CNS harbours stem cells. We were able to culture neurospheres from postmortem adult human material using a protocol we described recently (Leonard et al., 2009) (Fig. 6A ). We isolated NSCs from each donor that came to autopsy and this was successful for 80% of the cases. As previously described, we could obtain neurospheres ( Fig. 6A ) from elderly donors with and without neurodegenerative diseases. We found that GFAP-d is indeed expressed in proliferative and multi-potent neurospheres. In all the cultures that we stained for GFAP-d, we could find immunoreactivity ( Fig. 6B-E) , overlapping the expression of GFAP-a ( Fig. 6B) , nestin (Fig. 6C) , and vimentin (Fig. 6D ). In the neurospheres, expression of GFAP-d and the early neuronal marker b-III-tubulin was found mainly in distinct cell populations (Fig. 6E ). Detailed analysis of co-labelling using confocal microscopy, showing co-localization with GFAP-a, nestin and vimentin, but not b-III-tubulin can be found in supplemental Fig. S4 . We confirmed the expression of GFAPd at the RNA level by qPCR in different individual neurospheres from several donors (data not shown). We also found GFAP-d to be expressed in newly differentiated astrocytes (Fig. 6F ). This is in contrast to our findings in primary astrocyte cultures isolated from adult human brain, where it was rare to see GFAP-d staining (unpublished data).
Discussion
In this study, we have shown that GFAP-d expressing cells are present throughout the aged human SVZ, RMS, OT, and OB. In the SVZ and OB, GFAP-d is expressed in a subpopulation of proliferative astrocytes that express stem cell and proliferation markers and retain BrdU longterm; and in the RMS in the glial net. We also show that GFAP-d positive cells are present in neurospheres isolated from postmortem adult SVZ. Taken together, our data provide evidence that GFAP-d expressing cells in the aged human brain are slow-cycling neurogenic astrocytes and thus NSCs. GFAP-d expression was found along the entire length of the SVZ of the lateral ventricles in a ribbon-like pattern. The width of this ribbon and the intensity of the expression in the brain material studied were variable within cases and between cases. It is known that there is a variation in hippocampal neurogenesis, of up to 300%, between different strains of mice, implying that genetic factors influence neurogenesis considerably (Kempermann et al., 2006) . Genetic differences could therefore explain the variability in the number of NSCs, and thus the number of GFAP-d cells. Alternatively, growth factors are very important in stem cell regulation. For instance, VEGF and EGF influence GFAP-positive cells in the SVZ (Gonzalez-Perez et al., 2009; Mani et al., 2010) . These and other growth factors might influence the splicing of GFAP in this region. Other than genetics and growth factors, there are many factors that influence neurogenesis (reviewed in (Zhao et al., 2008) ), such as age, exercise, nicotine and a number of medications. However, the variability we observed in the GFAP-d ribbon could not be explained by any of these factors, which were described in the medical files of the donors.
The cyto-architecture of the human SVZ has been described before (Quinones-Hinojosa et al., 2006) , also with respect to the GFAP-positive astrocytic ribbon. In part, we observed a similar pattern for pan-GFAP expression, although we saw more variation in pan-GFAP staining patterns between donors. In the control donors we used, we observed a ribbon of GFAP positive cells directly adjacent to the hypocellular gap. For GFAP-d, we saw a ribbon of positive cells in the same location as described before (Roelofs et al., 2005) , where fewer cells were stained for GFAPd compared to pan-GFAP. Moreover, pan-GFAP expression could be found throughout the adjacent parenchyma, whereas GFAP-d staining is almost undetectable in these regions. Our data suggest that GFAP-d expression is restricted to the subpopulation of neurogenic astrocytes in the astrocytic ribbon of the SVZ.
We support this view by showing that the GFAP-d expressing cells in the SVZ are an immature subpopulation of astrocytes that have clear NSC-like features. These cells expressed the immature astrocyte marker vimentin, and the general astrocyte marker GFAP-a (Eng et al., 2000) . Furthermore, the GFAP-d positive cells lacked expression of GS, a marker for fully differentiated astrocytes, and of S100B, which in the rodent is not present in NSCs, but more mature astrocytes in the SVZ (Raponi (Maiorano et al., 2006) , and BrdU indicates that these cells are proliferative. Additionally, Sox2, a transcription factor important for the maintenance of NSCs (Graham et al., 2003) , is co-expressed with GFAP-d. The retention of BrdU in GFAP-d positive cells months after the BrdU injection suggests that these cells are slow-cycling. For the NSC marker nestin, we found a variable pattern of double-staining with GFAP-d, with numerous cells expressing both proteins, but also cells expressing either of the IF proteins. While nestin is widely used as a marker for NSCs, previous studies have shown that expression is not restricted to precursor cells and that there is little overlap with GFAP staining in the human SVZ (Gu et al., 2002) . We were unable to reproduce this last finding; instead we saw considerable overlap in staining in certain regions, but this might be an illustration of the variability one might observe in nestin-GFAP patterns or a difference in the antibodies that were used for GFAP. We could not find double-labelling with the proliferation markers pHH3 and Ki-67, but it must be noted that only a few cells expressing these proteins could be found, consistent with previous reports (Kukekov et al., 1999; Quinones-Hinojosa et al., 2006) . This might be because of the very tight regulation of these proteins, i.e. the short half-life of Ki-67 (Mandyam et al., 2007) , and the regulation of phosphorylation of the histone H3 protein (Juan et al., 1998) . NSCs are slowcycling cells (Doetsch et al., 1997) , and therefore it is not surprising that tightly regulated proliferation markers are only sparsely observed, or even not observed at all, in the aged human neurogenic brain areas. We only rarely observed co-expression between GFAP-d and EGF-R, a marker for C-cells, and between GFAP-d and b-III-tubulin, an A-cell marker, substantiating that the GFAP-d-positive astrocytes are B-cells.
In the RMS, we observed GFAP-d staining mostly in glial cells surrounding the stream of neuroblasts. The cyto-architecture of the human RMS differs from the rodent, where there is a typical GFAP-positive glial tube (Peretto et al., 1997) , which is rich in extracellular matrix components (Thomas et al., 1996) . In the human brain, the neuroblasts in the RMS are surrounded by a glial 'net' or 'mesh' (Kam et al., 2009) , as in the rabbit (Fasolo et al., 2002) and adult rhesus monkey brain (Pencea et al., 2001) . The basic structural organization seen in the SVZ is maintained in the RMS on the side adherent to the caudate nucleus and the ependymal structure, whereas limited SVZ components are maintained on the septal or medial side of the RMS (Kam et al., 2009) . From work in rodents and human material, it is clear that the RMS itself still contains precursor cells (Gritti et al., 2002; Alonso et al., 2008; Mendoza-Torreblanca et al., 2008; Kam et al., 2009) , but from recent work, it appears unlikely that these are GFAP-positive in human adult brain, as no PCNA+ ⁄ G-FAP+ cells were found (Kam et al., 2009) , which is in line with our results for PCNA and GFAP-d in this area. Thus, in the RMS, GFAP-d is most likely only expressed in cells of the glial net surrounding the migrating neuroblasts.
In the OB, GFAP-d was found mostly in the glomerular layer, which is one of the regions where neuroblast migration termi-nates in rodents and where neuronal turnover takes place throughout life (Bagley et al., 2007) . In the human brain, putative precursor cells were found within several areas of the OB, among which is the glomerular layer (Liu & Martin, 2003; Bedard & Parent, 2004) . In our experiments in the human OB, we saw that GFAP-d expressing cells expressed PCNA, indicating local proliferation of these cells. This makes these cells excellent candidates for the putative precursor cells described before in this area.
To investigate GFAP-d in the process of neurogenesis more in depth, we established postmortem human neurosphere cultures, which we described recently (Leonard et al., 2009) . In this in vitro model for NSCs, we found GFAP-d expression at mRNA and protein level. GFAP-d positive cells could be found throughout the neurospheres, co-expressing GFAP-a, nestin and vimentin. As in the human adult SVZ, we observed that GFAP-d and the early neuronal marker b-IIItubulin were expressed in mostly distinct cell populations. From these results, we can conclude that GFAP-d is most likely expressed in neural precursor cells of the adult human brain, as we have found for the foetal human brain (Middeldorp et al., 2010) . We are aware of the fact that the ultimate proof is still lacking, as we cannot isolate the GFAP-d cells specifically to subject them to the neurosphere assay. For this purpose, we need to find specific cell-surface markers on GFAP-d cells, enabling us to isolate them through FACsorting. Another observation from the neurosphere culture system was that newly differentiated astrocytes highly expressed GFAP-d, as demonstrated previously (Leonard et al., 2009) , which is not the case in primary astrocytes isolated directly from postmortem human brain. This indicates that GFAP-d is also an indicator of the differentiation state of cells.
The fact that NSCs express GFAP-d has important functional implications. Firstly, GFAP-d can destabilize the existing cytoskeleton of a cell (Nielsen & Jorgensen, 2004; Roelofs et al., 2005; Perng et al., 2008) , which might make a cell more flexible. This can potentially facilitate proliferation, as it is known that a cell must retract its processes, before division (Coskun et al., 2007) . Also, an increased flexibility of the cytoskeleton is necessary for the migratory capacity of cells, and GFAP has been shown to have an effect on astrocyte motility (Lepekhin et al., 2001) . GFAP-d could thus alter motility of migrating cells as well, by altering the properties of the cytoskeleton. This is in part supported by the morphology of GFAP-d cells, which are often elongated in a direction parallel to the ependymal lining of the SVZ. Another aspect of GFAP-d expression in NSCs is its influence on cell signalling, as it can modulate Notch (Nielsen et al., 2002) and Jnk (Perng et al., 2008) signalling. An example of IF-mediated signalling is the regulation of the apoptosisinducing activity of Cdk5 by nestin (Pallari & Eriksson, 2006) , which may be the function of nestin in NSCs. A possible function of GFAP-d in NSCs might be the modulation of Notch and ⁄ or Jnk signalling in stem cells. In summary, we observed GFAP-d expression in quiescent NSCs in the adult human SVZ, in cells of the glial net of the RMS, in precursor cells in the OB, and in newly differentiated astrocytes in vitro. These results are based on co-localization studies with several markers of neurogenesis, which have been validated extensively in rodents. For humans, results have been more ambiguous, e.g. for nestin (Gu et al., 2002) and doublecortin (Verwer et al., 2007) . Therefore, all results from human studies must be interpreted with caution, but we believe that with the various markers we have used, we can state that GFAPd is most likely a marker for NSCs ⁄ B-cells at least in the SVZ. The presence of GFAP-d in some C-and A-cells and young astrocytes could represent a transitional stage between the stem cells and their differentiated progeny. Expression of GFAP-d in the RMS glial net suggests that it may also be important for the neurogenic niche. GFAP-d positive cells in the OB may represent local precursor cells, but the stem cell pool in this region of the human brain has not been studied extensively yet.
Understanding the regulation of neurogenic cells is of importance with regard to neurological disorders where replacement of neurons is necessary, such as in Alzheimer's disease, Parkinson's disease, and stroke. The fact that NSCs can be found even in the aged human brain (Leonard et al., 2009) gives hope that when the precise regulation of NSCs is understood, endogenous repair by these cells may be feasible.
Experimental procedures
Postmortem human brain material Tissue from the SVZ, RMS, and OB was obtained from the Netherlands Brain Bank (NBB; Amsterdam, The Netherlands) and the department of Anatomy and Neurosciences (ANW), VU University Medical Centre (Amsterdam, The Netherlands). The NBB and ANW perform brain autopsies with regularly short postmortem intervals, and the brain donors have given informed consent for using the tissue and for accessing the extensive neuropathological and clinical information for scientific research, in compliance with ethical and legal guidelines (Huitinga et al., 2008) . Clinico-pathological information of all donors can be found in Table 1 .
SVZ material SVZ tissue for immunohistochemistry was sampled from three standardized areas in the brain as depicted in Fig. 1A . SVZ1 was dissected out at the level of the most frontal part of the caudate nucleus; SVZ2 came from the area beneath the cingulate gyrus; SVZ3 contained the most posterior part of the lateral ventricle. In SVZ1, both white and grey matter could be found aligning the SVZ, while in SVZ2 and SVZ3 only white matter was seen. The donor brain tissue for this part of our (Braak and Braak, 1991) and amyloid (Thal et al., 2000) pathology; PMD, postmortem delay; CSF, cerebrospinal fluid; pH CSF indicates the agonal state of the donor (Ravid et al., 1992) . study was selected using the following criteria: the clinical history of donors was free from any neurological disease or neuropsychiatric disorder; their brains did not have an Alzheimer Braak score higher than 3 or significant Parkinson's disease pathology. Furthermore, we excluded donors who had recently used medication that might affect neurogenesis, i.e. anti-mitotics and anti-depressants.
For neurosphere cultures, SVZ tissue was freshly isolated from the anterior horn of the SVZ. As we were restricted to the material that we could obtain from the NBB and the fact that the full neuropathological report is not available at the starting point of culturing, we included in this part of the study also patients with neurological and neuropsychiatric diseases.
BrdU material
Striatal tissue containing the SVZ was used from two donors who had received BrdU for diagnostic purposes as previously described (Eriksson et al., 1998) . Case 1 was female and received BrdU 129 days before death. Case 2 was also female and died 1693 days after BrdU administration.
RMS and OB material
Tissue of the human forebrain comprising the region surrounding the anterior horn of the lateral ventricle, frontal part of the caudate nucleus, gyrus rectus, substantia perforata anterior and OT, was sampled to study the RMS. Samples of the OT and OB were collected and processed for immunohistochemistry as well. The control donors for analysis of the RMS and OB were selected as for the SVZ. All tissue was immersion-fixed in phosphate-buffered 4% paraformaldehyde (PFA; pH 7.4) for 4 weeks before processing.
Immunostaining
Immunostaining was performed according to a fairly standard protocol, described in full in the supplemental data. Briefly, epitope retrieval was performed in a steamer and a serum-blocking step was used before incubating with antibody (supplementary Table S1 ) overnight. The antibodies were visualized using biotinylated secondary antibodies, ABC, and DAB, or fluorescently labelled secondary antibodies.
Human postmortem neurospheres cultures
Neurosphere cultures were initiated as described previously (Leonard et al., 2009) . The obtained microglia-poor cell pellet was taken up in serum-free medium (SFM, Neurobasal medium, 1% B27, 0.5% N2, 1% Glutamax, 1% P ⁄ S, Hepes (all Invitrogen, Carlsbad, CA, USA), 1% Ultraglutamin (Cambrex Corporation, East Rutherford, NJ, USA), 5 lg mL )1 heparin (Sigma, St. Louis, MO, USA), 20 ng mL )1 epidermal growth factor (EGF), and 20 ng mL )1 fibroblast growth factor (FGF; both Tebu-Bio, Paris, France) and plated in a 12-well plate. For differentiation, spheres were centrifuged and replated in complete Dulbecco's Modified Eagle Medium (DMEM; containing 10% fetal calf serum, 1% P/S, Hepes; all Invitrogen) on 12-mm poly-L-lysine-coated glass coverslips.
For quantitative real-time polymerase chain reaction (qPCR), single neurospheres were isolated and taken up in 100 lL Trizol (Invitrogen). RNA was isolated according to the manufacturer's protocol, with addition of glycogen to facilitate RNA precipitation. A DNase (Invitrogen) step was used to degrade genomic DNA contamination. cDNA synthesis and qPCR for GFAP-d were performed as previously described (Perng et al., 2008) .
For immunostaining, the neurospheres were fixed for 20 min in 3.7% formaldehyde solution (Sigma) in phosphate-buffered saline (PBS; 50 mM potassium phosphate, 150 mM NaCl; pH 7.2), after which they were embedded in TissueTek (Bayer, Leverkusen, Germany) for cryosectioning and mounted on Superfrost plus slides. Differentiated cells were fixed with formaldehyde solution in PBS on coverslips. Then, the 10-lm thick cryosections or coverslips were washed in TBS and incubated with antibodies (see supplementary Table S1) in TBS-BSA for 16-24 h at 4°C. After three rinses with TBS, secondary antibodies in TBS-BSA were applied for 1 h at RT. Then, the sections or coverslips were rinsed three times and embedded in Mowiol.
Image acquisition and analysis
Images of single immunostainings were obtained on an Axio-Skop microscope (Zeiss, Oberkochen, Germany) with Neoplanfluor objectives, using a Sony XC77 black and white camera (Sony, San Diego, CA, USA) and ImagePro software (MediaCybernetics, Bethesda, MD, USA). Images of immunofluorescent staining were obtained on an AxioPlan 2 microscope (Zeiss) with Planapochromat objectives, using an Evolution QEi black and white camera (MediaCybernetics) and ImagePro software. Confocal images were obtained on a Zeiss LSM 510 Meta Confocal Microscope (Zeiss).
For the quantification of the width of the GFAP-d ribbon, low magnification images were taken of the whole SVZ present in one section. In this image, an area of interest (AOI) was drawn around the SVZ. In this AOI, 5 images were captured at high magnification in a randomized way. In the high magnification image, again an AOI was drawn, this time around the GFAP-d-positive area. The average width of this AOI was measured and used as the width of GFAP-d staining.
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